Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study

'מערכת אימד' 31/12/2021 15:17

Abstract

Background

Major depressive disorder (MDD) is the leading cause of disability worldwide. Response to pharmacologic treatment is generally evaluated by traditional clinician- and patient-reported rating scales.

להמשך קריאה

2021; 21: 622.

Published online 2021 Dec 11. doi: 10.1186/s12888-021-03608-1